Valuation: Lexicon Pharmaceuticals, Inc.

Market Cap 1.06B 930M 860M 791M 1.49B 102B 1.52B 10.27B 4.03B 50.05B 3.99B 3.9B 172B P/E 2026 *
-15.2x
P/E 2027 * -12.6x
Enterprise Value 1.06B 930M 860M 791M 1.49B 102B 1.52B 10.27B 4.03B 50.05B 3.99B 3.9B 172B EV / Sales 2026 *
27.8x
EV / Sales 2027 * 52.7x
Free-Float
98.45%
Yield 2026 *
-
Yield 2027 * -
1 day-2.51%
1 week+4.95%
Current month-2.92%
1 month+15.92%
3 months+24.60%
6 months+70.07%
Current year+102.61%
1 week 2.04
Extreme 2.04
2.42
1 month 1.98
Extreme 1.985
2.68
Current year 1.1
Extreme 1.1
2.68
1 year 1
Extreme 1
2.68
3 years 0.28
Extreme 0.2836
3.73
5 years 0.28
Extreme 0.2836
6.33
10 years 0.28
Extreme 0.2836
19.62
Manager TitleAgeSince
Chief Executive Officer 56 08/07/2024
Director of Finance/CFO 59 02/01/2025
Chief Tech/Sci/R&D Officer - 01/02/2025
Director TitleAgeSince
Chairman 83 01/01/2005
Chairman 71 27/02/2012
Director/Board Member 67 28/08/2007
Date Insider Type Main position Quantity % Market Cap.
03/06/26 Fiscal year

Director

178,624 0.0402%
03/06/26
The Invus Group LLC
OtherCompany 0 0%
03/06/26 Fiscal year

Director

178,624 0.0402%
Change 5-day change 1-year change 3-year change Capi.($)
-2.51%+4.95%+89.43%+6.88% 1.06B
+0.21%-1.34%+53.17%+60.65% 53.83B
+5.37%+0.75%+50.39%+83.03% 52.1B
-1.20%-7.43%+4.35%+406.96% 23.48B
+0.74%+0.73%-16.23%-15.55% 23.13B
+3.46%+0.79%+34.01%-4.47% 19.36B
-1.18%-1.15%+30.12%-32.02% 17.56B
-1.67%-8.56%+163.95%+284.69% 15.2B
+3.62%-2.42%+29.70%+663.64% 14.83B
-0.70%-1.72%+24.87%+184.19% 14.06B
Average +0.61%-1.43%+46.37%+163.80% 23.46B
Weighted average by Cap. +1.46%-2.30%+41.68%+140.24%

Financials

2026 *2027 *
Net sales 38.17M 33.44M 30.92M 28.43M 53.73M 3.68B 54.57M 369M 145M 1.8B 143M 140M 6.2B 20.15M 17.66M 16.33M 15.01M 28.37M 1.94B 28.82M 195M 76.43M 950M 75.67M 74.02M 3.27B
Net income -66.94M -58.65M -54.23M -49.86M -94.23M -6.46B -95.71M -647M -254M -3.16B -251M -246M -10.88B -88.26M -77.34M -71.51M -65.75M -124M -8.51B -126M -854M -335M -4.16B -331M -324M -14.34B
Net Debt - -
Logo Lexicon Pharmaceuticals, Inc.
Lexicon Pharmaceuticals, Inc., is a biopharmaceutical company. The Company is engaged in research and development of drug candidates and the commercialization of the drug, INPEFA (sotagliflozin). INPEFA reduces the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure or type 2 diabetes, chronic kidney disease (CKD), and other cardiovascular risk factors. Sotagliflozin is an orally delivered small molecule drug candidate as a treatment for hypertrophic cardiomyopathy (HCM) and conducts the SONATA-HCM pivotal Phase 3 clinical trial of sotagliflozin in that indication. The Company develops pilavapadin, an orally delivered small molecule drug candidate, as a treatment for neuropathic pain. The Company also develops LX9851, an orally delivered small molecule drug candidate, for the treatment of obesity and associated cardiometabolic disorders.
Employees
81
Date Price Change Volume
20/07/26 $2.330 -2.51% 3,095,493
17/07/26 $2.390 +6.70% 2,431,579
16/07/26 $2.240 +1.82% 2,736,852
15/07/26 $2.200 +3.77% 4,408,666
14/07/26 $2.120 -2.30% 1,541,127
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
CCC
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
5
Last Close Price
2.390USD
Average target price
3.770USD
Spread / Average Target
+57.74%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. LXRX Stock